#31/F

Goiga

Jand Delivery

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Brooks, et al.

Serial No.: 09/081,522

) Group Art Unit: 1644
)

Filed: May 19, 1998

Title: INHIBITION OF ANGIOGENESIS
IN DISEASE STATES WITH AN
ANTI-ανβ3 MONOCLONAL

) Confirmation No. 1607

ANTIBODY (AS AMENDED)

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.114

Our Ref.: TSRI 419.0 Con 1

Commissioner for Patents Mail Stop RCE P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In response to the Final Office Action mailed March 17, 2003, and pursuant to 37 CFR § 1.114, please enter the following amendments and consider the following remarks in connection with the above-identified patent application. A personal interview with the Examiner was held on September 9, 2003. Applicants submit concurrently herewith (a) a Request for Continued Examination under 37 C.F.R. § 1.114 accompanied by the appropriate fees; (b) an Amendment Fee Transmittal Sheet; (c) a supplemental Information Disclosure Statement, accompanied by a Supplemental List of References Cited by the Applicant, along with copies of the cited references; and (d) a Petition for Extension of Time for a period of three (3) months from June 17, 2003 to and including September 17, 2003. Accordingly, this response is timely filed.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 6 of this paper.

09/24/2003 GDUCKETT 00000001 190962 09081522 03 FC:1203 280.00 DA

7